RGM-C/Hemojuvelin Antibody

R&D Systems | Catalog # AF3720

R&D Systems

Key Product Details

Species Reactivity

Validated:

Human, Mouse

Cited:

Human, Transgenic Mouse

Applications

Validated:

Western Blot, Immunocytochemistry

Cited:

Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Goat IgG
Loading...

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human RGM-C isoform a (R&D Systems, Catalog # 3720-RG)
Gln36-Asp400
Accession # Q6ZVN8

Specificity

Detects human and mouse RGM-C in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross‑reactivity with recombinant human (rh) RGM-B is observed and less than 5% cross-reactivity with rhRGM-A is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for RGM-C/Hemojuvelin Antibody

RGM-C/Hemojuvelin antibody in HepG2 Human Cell Line by Immunocytochemistry (ICC).

RGM‑C/Hemojuvelin in HepG2 Human Cell Line.

RGM-C/Hemojuvelin was detected in immersion fixed HepG2 human hepatocellular carcinoma cell line using Goat Anti-Human/Mouse RGM-C/Hemojuvelin Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3720) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.
Detection of RGM-C/Hemojuvelin by Western Blot

Detection of RGM-C/Hemojuvelin by Western Blot

HFE2 administration significantly improves EAE disease outcome.a Western Blot analysis shows a strong HFE2 reduction in EAE animal serum when compared to control. ELISA quantification showing HFE2 decrease and RGMa increase in EAE animal serum (mean ± s.d.; EAE n = 3 and RGMa n = 3). b Body conditioning assessment (‘0’ no paralysis to ‘4’ forelimb weakness) of EAE-induced mice with HFE2 + /- RGMa treatment every 3 days (d3, 6, 9, 12 and 15; mean ± s.e.m.; unpaired two-tail t-tests; PBS n = 8, HFE2 n = 6, RGMa+ HFE2 n = 8). c Body conditioning assessment of EAE-induced Hfe2fl/fl and Hfe2 delta Alb-cre mice (mean ± s.e.m.; unpaired two-tail t-tests; Hfe2fl/fln = 8 and Hfe2 delta Alb-cren = 8). d Representative confocal images of CD3 +, B220+ and CD11b+ immune staining in spinal cord of EAE-induced mice 3 weeks after induction and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS n = 7, HFE2 n = 6 mice; technical replicates shown). e Schematic of activated immune cell adoptive transfer. Representative confocal images of CD4-positive labelled transferred cell (CellVue) in PBS-treated or HFE2-treated recipient WT mice and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS n = 6, HFE2 n = 6). Ptx; Pertussis Toxin. f Representative confocal images of fibrinogen in the spinal cord of HFE2-treated EAE-mice and quantification (mean ± s.e.m.; unpaired two-tail t-test; PBS-treated n = 6 and HFE2 n = 6). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38310100), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-C/Hemojuvelin by Immunohistochemistry

Detection of RGM-C/Hemojuvelin by Immunohistochemistry

Hfe2-deficient mice displays severe BCB disruption.a Schematic of the BCB assessment method using light-sheet microscopy. b 3D rendered representative light-sheet microscopic images of TR-dextran deposition in CUBIC-cleared brains (scale bars, 400 µm) and time-series quantification (mean ± s.e.m.; unpaired two-tail t-test; Hfe2fl/fl (control) n = 5, Hfe2 delta AlbCren = 6, AAV8-GFP n = 5, AAV8-AlbCre n = 7; n representing data generated from one brain). c Representative in-vivo multiphoton images of TR-dextran at 40 mins time-point (scale bar, 50 µm) from the parietal lobes of the cerebral cortex. The normalized extravascular fluorescence ( delta F/F) intensity was plotted over time (mean ± s.e.m.; unpaired two-tail t-tests) and the groups differences were assessed with spatial leakage log-likelihood (repeated measures factorial ANOVA rendered as approximate unpaired two-tail t-test; Hfe2fl/fln = 5, Hfe2 delta AlbCren = 10, AAV8-GFP n = 6, AAV8-AlbCre n = 5). d Representative confocal images of fibrinogen disposition around the vessels of cerebral cortex (isolectin) of Hfe2-deficient mice (scale bar, 50 µm) and quantification (mean ± s.e.m.; unpaired two-tail t-test; Hfe2fl/fln = 4, Hfe2 delta AlbCren = 5, AAV8-GFP n = 5, AAV8-AlbCre n = 6). e Confocal imaging of TR-dextran deposition in brain slices from the cerebral cortex with endothelium counterstain. The same observation was made in sections from 3 AAV8-GFP and 3 AAV8-AlbCre brains. f 3D rendered representative light-sheet microscopic images of TR-dextran deposition in CUBIC-cleared brains (scale bars, 400 µm; mean ± s.e.m.; unpaired two-tail t-test; Hfe2fl/fln = 5, Hfe2 delta ActaCren = 6). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38310100), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-C/Hemojuvelin by Immunohistochemistry

Detection of RGM-C/Hemojuvelin by Immunohistochemistry

Soluble HFE2 and RGMa effects on endothelial cells.a Knockout of liver Hfe2 reduces pericyte coverage in section from the cerebral cortex (mean ± s.e.m.; unpaired two-tail t-test; AAV8-GFP n = 3, Hfe2 delta Alb-cren = 4, and AAV8-AlbCre n = 3). Scale bar, 50μm. b Quantification through quantitative RT-PCR shows a reduction in PDGF-B mRNA levels in liver knock out animals (mean ± s.e.m.; paired two-tail t-test; Hfe2fl/fln = 3 and Hfe2 delta Alb-cren = 3). c Quantification of PDGF-B mRNA in cultured bEnd.3 cells following indicated treatments. Treatment with RGMa leads to a significant reduction of PDGF-B mRNA levels that is rescued with HFE2 addition (mean ± s.e.m.; paired two-tail t-test; HFE2 n = 3, RGMa n = 4, and RGMa+ HFE2 n = 5; n representing an independent experiment). d Immunocytochemistry of claudin-5 in human primary endothelial cell monolayer after PBS, HFE2, RGMa, and RGMa+HFE2 treatments and quantification (mean ± s.e.m.; unpaired two-tail t-test; replicates n = 3). Scale bar, 100 µm. e Western blotting of Claudin-5 expression in bEnd3 cell lysates after indicated treatment (mean ± s.e.m.; unpaired two-tailed t-test; replicates n = 3). f Transwell permeability leakage assay performed on a monolayer of bEnd3 cells using HRP (mean ± s.e.m.; paired one-tail t-test; replicates n = 3). g Transwell permeability leakage assay performed on a monolayer of human primary endothelial cells using 70 kDa FITC-dextran (mean ± s.e.m.; paired two-tail t-test; replicates n = 3). h In vitro TEER analysis shows that RGMa alters the integrity of a monolayer of bEnd3 cells, this is rescued by HFE2 (mean ± s.e.m.; unpaired two-tail t-test; replicates n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38310100), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-C/Hemojuvelin by Immunohistochemistry

Detection of RGM-C/Hemojuvelin by Immunohistochemistry

Hfe2-deficient mice displays severe BCB disruption.a Schematic of the BCB assessment method using light-sheet microscopy. b 3D rendered representative light-sheet microscopic images of TR-dextran deposition in CUBIC-cleared brains (scale bars, 400 µm) and time-series quantification (mean ± s.e.m.; unpaired two-tail t-test; Hfe2fl/fl (control) n = 5, Hfe2 delta AlbCren = 6, AAV8-GFP n = 5, AAV8-AlbCre n = 7; n representing data generated from one brain). c Representative in-vivo multiphoton images of TR-dextran at 40 mins time-point (scale bar, 50 µm) from the parietal lobes of the cerebral cortex. The normalized extravascular fluorescence ( delta F/F) intensity was plotted over time (mean ± s.e.m.; unpaired two-tail t-tests) and the groups differences were assessed with spatial leakage log-likelihood (repeated measures factorial ANOVA rendered as approximate unpaired two-tail t-test; Hfe2fl/fln = 5, Hfe2 delta AlbCren = 10, AAV8-GFP n = 6, AAV8-AlbCre n = 5). d Representative confocal images of fibrinogen disposition around the vessels of cerebral cortex (isolectin) of Hfe2-deficient mice (scale bar, 50 µm) and quantification (mean ± s.e.m.; unpaired two-tail t-test; Hfe2fl/fln = 4, Hfe2 delta AlbCren = 5, AAV8-GFP n = 5, AAV8-AlbCre n = 6). e Confocal imaging of TR-dextran deposition in brain slices from the cerebral cortex with endothelium counterstain. The same observation was made in sections from 3 AAV8-GFP and 3 AAV8-AlbCre brains. f 3D rendered representative light-sheet microscopic images of TR-dextran deposition in CUBIC-cleared brains (scale bars, 400 µm; mean ± s.e.m.; unpaired two-tail t-test; Hfe2fl/fln = 5, Hfe2 delta ActaCren = 6). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38310100), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-C/Hemojuvelin by Immunohistochemistry

Detection of RGM-C/Hemojuvelin by Immunohistochemistry

Hfe2-deficient mice displays severe BCB disruption.a Schematic of the BCB assessment method using light-sheet microscopy. b 3D rendered representative light-sheet microscopic images of TR-dextran deposition in CUBIC-cleared brains (scale bars, 400 µm) and time-series quantification (mean ± s.e.m.; unpaired two-tail t-test; Hfe2fl/fl (control) n = 5, Hfe2 delta AlbCren = 6, AAV8-GFP n = 5, AAV8-AlbCre n = 7; n representing data generated from one brain). c Representative in-vivo multiphoton images of TR-dextran at 40 mins time-point (scale bar, 50 µm) from the parietal lobes of the cerebral cortex. The normalized extravascular fluorescence ( delta F/F) intensity was plotted over time (mean ± s.e.m.; unpaired two-tail t-tests) and the groups differences were assessed with spatial leakage log-likelihood (repeated measures factorial ANOVA rendered as approximate unpaired two-tail t-test; Hfe2fl/fln = 5, Hfe2 delta AlbCren = 10, AAV8-GFP n = 6, AAV8-AlbCre n = 5). d Representative confocal images of fibrinogen disposition around the vessels of cerebral cortex (isolectin) of Hfe2-deficient mice (scale bar, 50 µm) and quantification (mean ± s.e.m.; unpaired two-tail t-test; Hfe2fl/fln = 4, Hfe2 delta AlbCren = 5, AAV8-GFP n = 5, AAV8-AlbCre n = 6). e Confocal imaging of TR-dextran deposition in brain slices from the cerebral cortex with endothelium counterstain. The same observation was made in sections from 3 AAV8-GFP and 3 AAV8-AlbCre brains. f 3D rendered representative light-sheet microscopic images of TR-dextran deposition in CUBIC-cleared brains (scale bars, 400 µm; mean ± s.e.m.; unpaired two-tail t-test; Hfe2fl/fln = 5, Hfe2 delta ActaCren = 6). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38310100), licensed under a CC-BY license. Not internally tested by R&D Systems.
Detection of RGM-C/Hemojuvelin by Western Blot

Detection of RGM-C/Hemojuvelin by Western Blot

Soluble HFE2 and RGMa effects on endothelial cells.a Knockout of liver Hfe2 reduces pericyte coverage in section from the cerebral cortex (mean ± s.e.m.; unpaired two-tail t-test; AAV8-GFP n = 3, Hfe2 delta Alb-cren = 4, and AAV8-AlbCre n = 3). Scale bar, 50μm. b Quantification through quantitative RT-PCR shows a reduction in PDGF-B mRNA levels in liver knock out animals (mean ± s.e.m.; paired two-tail t-test; Hfe2fl/fln = 3 and Hfe2 delta Alb-cren = 3). c Quantification of PDGF-B mRNA in cultured bEnd.3 cells following indicated treatments. Treatment with RGMa leads to a significant reduction of PDGF-B mRNA levels that is rescued with HFE2 addition (mean ± s.e.m.; paired two-tail t-test; HFE2 n = 3, RGMa n = 4, and RGMa+ HFE2 n = 5; n representing an independent experiment). d Immunocytochemistry of claudin-5 in human primary endothelial cell monolayer after PBS, HFE2, RGMa, and RGMa+HFE2 treatments and quantification (mean ± s.e.m.; unpaired two-tail t-test; replicates n = 3). Scale bar, 100 µm. e Western blotting of Claudin-5 expression in bEnd3 cell lysates after indicated treatment (mean ± s.e.m.; unpaired two-tailed t-test; replicates n = 3). f Transwell permeability leakage assay performed on a monolayer of bEnd3 cells using HRP (mean ± s.e.m.; paired one-tail t-test; replicates n = 3). g Transwell permeability leakage assay performed on a monolayer of human primary endothelial cells using 70 kDa FITC-dextran (mean ± s.e.m.; paired two-tail t-test; replicates n = 3). h In vitro TEER analysis shows that RGMa alters the integrity of a monolayer of bEnd3 cells, this is rescued by HFE2 (mean ± s.e.m.; unpaired two-tail t-test; replicates n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. Source data are provided as a Source Data file (includes exact p-values). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38310100), licensed under a CC-BY license. Not internally tested by R&D Systems.

Applications for RGM-C/Hemojuvelin Antibody

Application
Recommended Usage

Immunocytochemistry

5-15 µg/mL
Sample: Immersion fixed HepG2 human hepatocellular carcinoma cell line

Western Blot

0.1 µg/mL
Sample:

Recombinant Human RGM-C (Catalog # 3720-RG)

Recombinant Mouse RGM-C (Catalog # 3634-RG)

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.


Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

Shipping

Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: RGM-C/Hemojuvelin

RGM-C, also known as hemojuvelin, is a member of the repulsive guidance molecule (RGM) family of GPI-linked neuronal and muscle membrane glycoproteins (1, 2). RGM-C is expressed in striated muscle and periportal hepatocytes (3-5). The protein undergoes partial cleavage intracellularly, resulting in a disulfide-linked dimer of the 14 kDa N-terminal and 33 kDa C-terminal portions (4, 6, 7). The N-terminal fragment contains an RGD motif, while the C-terminal fragment carries the GPI attachment site (4, 7). Two alternatively spliced isoforms lack either approximately half or the entire N-terminal fragment. Full length RGM-C can also be released from the cell and circulates in the blood (6, 8). RGM-C is disrupted in type 2A juvenile hemochromatosis, a hereditary iron homeostasis disorder characterized by excessive iron accumulation (5). In mouse, loss of RGM-C function results in decreased expression of the iron regulatory hormone hepicidin and increased iron deposition in liver, pancreas, and heart (5, 9). Membrane associated RGM-C upregulates hepicidin while soluble RGM-C downregulates hepicidin expression (8). This appears to be an iron-responsive regulatory system, as high blood iron levels reduce the amount of soluble RGM-C produced (8). RGM-C, similar to RGM-A, associates with neogenin (7). Disease-related point mutations can prevent internal RGM-C cleavage or its ability to interact with neogenin (6, 7). Experimental inflammatory conditions result in decreased RGM-C expression and increased hepicidin expression, although the two effects occur independently (5, 10). RGM-C also functions as a BMP coreceptor and enhances BMP-2 and BMP-4 signaling (11). In this context, RGM-C enhances the BMP-2 upregulation of hepatic hepicidin (11). Mature human RGM-C shares 89% amino acid (aa) sequence identity with mouse and rat RGM-C. It shares 49% and 44% aa sequence identity with human RGM-A and RGM-B, respectively.

References

  1. Papanikolaou, G. et al. (2004) Nat. Genet. 36:77.
  2. Schmidtmer, J. and D. Engelkamp (2004) Gene Exp. Patterns 4:105.
  3. Oldekamp, J. et al. (2004) Gene Exp. Patterns 4:283.
  4. Niederkofler, V. et al. (2004) J. Neurosci. 24:808.
  5. Niederkofler, V. et al. (2005) J. Clin. Invest. 115:2180.
  6. Kuninger, D. et al. (2006) J. Cell Sci. 119:3273.
  7. Zhang, A.S. et al. (2005) J. Biol. Chem. 280:33885.
  8. Lin, L. et al. (2005) Blood 106:2884.
  9. Huang, F.W. et al. (2005) J. Clin. Invest. 115:2187.
  10. Krijt, J. et al. (2004) Blood 104:4308.
  11. Babitt, J.L. et al. (2006) Nat. Genet. 38:531.

Long Name

Repulsive Guidance Molecule C

Alternate Names

DL-M, Hemojuvelin, HFE2, HJV, JH, RGMC

Entrez Gene IDs

148738 (Human); 69585 (Mouse); 310681 (Rat)

Gene Symbol

HJV

UniProt

Additional RGM-C/Hemojuvelin Products

Product Documents for RGM-C/Hemojuvelin Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for RGM-C/Hemojuvelin Antibody

For research use only

Related Research Areas

Citations for RGM-C/Hemojuvelin Antibody

Customer Reviews for RGM-C/Hemojuvelin Antibody

There are currently no reviews for this product. Be the first to review RGM-C/Hemojuvelin Antibody and earn rewards!

Have you used RGM-C/Hemojuvelin Antibody?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 for a review with an image

$10/€7/£6/$10CAN/¥1110 for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies
Loading...